- Home
- BLFS vs RCUS Comparison
BLFS vs RCUS Comparison
Compare BLFS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- RCUS
- Stock Information
- Founded
- BLFS 1987
- RCUS 2015
- Country
- BLFS United States
- RCUS United States
- Employees
- BLFS N/A
- RCUS N/A
- Industry
- BLFS Medical/Dental Instruments
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- RCUS Health Care
- Exchange
- BLFS Nasdaq
- RCUS Nasdaq
- Market Cap
- BLFS 1.2B
- RCUS 1.4B
- IPO Year
- BLFS 1989
- RCUS 2018
- Fundamental
- Price
- BLFS $26.14
- RCUS $14.02
- Analyst Decision
- BLFS Strong Buy
- RCUS Buy
- Analyst Count
- BLFS 7
- RCUS 12
- Target Price
- BLFS $29.43
- RCUS $34.50
- AVG Volume (30 Days)
- BLFS 277.1K
- RCUS 609.3K
- Earning Date
- BLFS 02-27-2025
- RCUS 02-19-2025
- Dividend Yield
- BLFS N/A
- RCUS N/A
- EPS Growth
- BLFS N/A
- RCUS N/A
- EPS
- BLFS N/A
- RCUS N/A
- Revenue
- BLFS $146,957,000.00
- RCUS $263,000,000.00
- Revenue This Year
- BLFS N/A
- RCUS $127.65
- Revenue Next Year
- BLFS N/A
- RCUS N/A
- P/E Ratio
- BLFS N/A
- RCUS N/A
- Revenue Growth
- BLFS 16.40
- RCUS 119.17
- 52 Week Low
- BLFS $14.50
- RCUS $13.51
- 52 Week High
- BLFS $28.88
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- BLFS 47.94
- RCUS 37.13
- Support Level
- BLFS $24.77
- RCUS $13.81
- Resistance Level
- BLFS $28.10
- RCUS $14.52
- Average True Range (ATR)
- BLFS 1.37
- RCUS 0.60
- MACD
- BLFS -0.11
- RCUS -0.09
- Stochastic Oscillator
- BLFS 39.48
- RCUS 22.97
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing, and marketing a portfolio of biopreservation tools and services for cells, tissues, and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.